Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2020-05-21 Major Shareholding Noti…
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
Holding(s) in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings'. It explicitly details a change in share ownership (Invesco Ltd. holding in Mereo BioPharma Group plc) and follows the regulatory format for major shareholding notifications as required by the FCA. This fits the definition of a Major Shareholding Notification (MRQ).
2020-05-21 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo BioPharma Group plc, with the SEC. It primarily announces the company's intention to delay the filing of its 2019 Annual Report on Form 20-F due to COVID-19 related disruptions. The document discusses the SEC relief order allowing the delay and outlines the impact of COVID-19 on the company's operations and clinical trials. It does not contain the actual annual report or financial statements but is an announcement regarding the timing of the report filing. The document length is about 10,353 characters, which is relatively short and focused on the announcement rather than the report itself. Therefore, according to the "Menu vs Meal" rule, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about the delay of a report filing, not the report itself.
2020-04-28 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo Biopharma Group PLC, pursuant to SEC rules under the Securities Exchange Act of 1934. It includes a press release as an exhibit and is signed by the General Counsel. The document length is short (1389 characters) and primarily serves as a regulatory filing to report current information rather than a full financial report or detailed presentation. Form 6-K filings are typically periodic reports for foreign issuers and fall under the category of Regulatory Filings (RNS) in this classification scheme.
2020-03-27 English
Business Update and Directorate Change
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from Mereo BioPharma Group plc. It covers two primary topics: a business update regarding the impact of COVID-19 on clinical trials and a formal announcement of a directorate change (the departure of the CFO and appointment of an interim successor). While it contains management information, the primary purpose of an RNS announcement of this nature, which combines operational updates and personnel changes, is best classified under the 'MANG' (Board/Management Information) category as it explicitly details the change in senior management.
2020-03-27 English
Regulatory Filings 2020
Regulatory Filings
2020-03-20 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC Division of Corporation Finance requesting acceleration of effectiveness for a Registration Statement on Form F-1. It is a formal correspondence related to a regulatory filing process, specifically about the timing of the registration statement becoming effective. The document does not contain financial data, report content, or detailed disclosures itself, but is a procedural request. Given the short length (1363 characters) and nature as a letter requesting acceleration of a filing, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2020-03-18 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.